Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Equity Ratio (2021 - 2025)

Prime Medicine filings provide 5 years of Equity Ratio readings, the most recent being 0.35 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 31.49% to 0.35 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.35, a 31.49% decrease, with the full-year FY2025 number at 0.35, down 31.49% from a year prior.
  • Equity Ratio hit 0.35 in Q4 2025 for Prime Medicine, down from 0.42 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.88 in Q1 2023 to a low of 1.04 in Q3 2022.
  • Median Equity Ratio over the past 5 years was 0.57 (2024), compared with a mean of 0.43.
  • Biggest five-year swings in Equity Ratio: surged 269.58% in 2022 and later tumbled 71.18% in 2025.
  • Prime Medicine's Equity Ratio stood at 0.52 in 2021, then surged by 269.58% to 0.88 in 2022, then decreased by 21.79% to 0.69 in 2023, then fell by 25.01% to 0.51 in 2024, then plummeted by 31.49% to 0.35 in 2025.
  • The last three reported values for Equity Ratio were 0.35 (Q4 2025), 0.42 (Q3 2025), and 0.22 (Q2 2025) per Business Quant data.